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Abstract
Demand for high quality gene expression data has driven the development of revolutionary microarray technologies. The
quality of the data is affected by the performance of the microarray platform as well as how the nucleic acid targets are
prepared. The most common method for target nucleic acid preparation includes in vitro transcription amplification of the
sample RNA. Although this method requires a small amount of starting material and is reported to have high reproducibility,
there are also technical disadvantages such as amplification bias and the long, laborious protocol. Using RNA derived from
human brain, breast and colon, we demonstrate that a non-amplification method, which was previously shown to be
inferior, could be transformed to a highly quantitative method with a dynamic range of five orders of magnitude.
Furthermore, the correlation coefficient calculated by comparing microarray assays using non-amplified samples with qRT-
PCR assays was approximately 0.9, a value much higher than when samples were prepared using amplification methods.
Our results were also compared with data from various microarray platforms studied in the MicroArray Quality Control
(MAQC) project. In combination with micro-columnar 3D-Gene
TM microarray, this non-amplification method is applicable to
a variety of genetic analyses, including biomarker screening and diagnostic tests for cancer.
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Introduction
Microarray permits the simultaneous analysis of hundreds of
thousands of genes in a relatively short time using a small amount
of sample material. The quality of expression data, however, is
affected not only by the microarray performance, but also by how
the nucleic acid targets are prepared. The most common method
for nucleic acid target preparation includes in vitro transcription
amplification of the sample RNA, which allows the initial amount
of starting material to be in the nano- or pico-gram range [1–3].
The amplification method is also reported to show high
reproducibility and strong correlation with qRT-PCR [4]. One
drawback of the amplification method is that it is a long and
intensive process, which also leads to increased labor costs.
Furthermore, the complicated protocol is difficult to adapt for
diagnostic or medical testing applications, which demand a quick
and simple process. However, perhaps the most concerning issue
regarding the amplification method is data accuracy. Amplifica-
tion bias that is generated during the in vitro transcription step may
distort the quantitative measurement of transcript abundance.
Accurate detection of gene transcript abundance as well as of
differential expression ratios is critical. Failure to accurately detect
these may have serious consequences, particularly when the results
obtained are applied to medical tests or clinical diagnoses.
A sample preparation protocol that does not require RNA
amplification exists and has been used since the beginning of the
microarray technology era [5]. However, with the increase in
available amplification methods, the non-amplification protocol has
been largelyreplaced, likely due to its requirement for a large amount
of RNA starting material. Currently, most microarray manufacturers
including Affymetrix [6–8], Agilent [9–11] and Illumina [12]
recommend using amplified RNA samples for gene expression
analysis to minimize the amount of starting RNA required.
We previously developed a novel microarray, 3D-Gene
TM,
which features a micro-columnar structure composed of black resin
substrate and a bead-agitation technique. This achieves low
background noise, enhanced signal intensity, and high reproduc-
ibility in detecting gene expression profiles [13]. The system has
demonstrated highsensitivity in microRNA detection [14] as well as
in multiplex single-nucleotide polymorphism (SNP) detection [15].
In this study, we used the 3D-Gene
TM microarray platform and
compared samples prepared using either a conventional amplifi-
cation protocol or a non-amplification protocol. Samples from the
non-amplification procedure had higher quantitative accuracy
than those from the amplification method, with competitive
detection power and reproducibility. Our results suggest that when
combined with micro-columnar 3D-Gene
TM microarray, the non-
amplification method for nucleic acid preparation is a reliable and
practical technique for gene expression profiling.
Results
Quantitative and qualitative reproducibility and
concordance
To assess the effect of amplification during sample RNA
preprocessing, we first examined the reproducibility of quantitative
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amplification, 1-round amplification or 2-round amplification
methods. Duplicate samples of Universal Human Reference RNA
(UHRR) were prepared by each of the three methods and
analyzed by microarray. The intra-method reproducibility was
similar among the three methods with a slight decrease in
Pearson’s correlation for the non-amplification method (Fig. 1A).
The proportions of genes in which signal intensity values were
detected within a range of 2-fold change in the duplicate
experiments were 98.1%, 99.2% and 97.9% for the non-, 1-
round and 2-round amplification methods, respectively. The
proportions of undetected genes were in a similar order: 7.5%,
3.8% and 10.8% of a total of 24,267 genes for the non-, 1-round,
and 2-round amplification methods. In contrast to the high intra-
method reproducibility, correlation values from inter-method
comparisons showed significantly reduced reproducibility. The
Pearson’s correlation value was 0.689 between the non- and 1-
round amplification, 0.863 between 1- and 2-round amplification
and 0.479 between the non- and 2-round amplification methods
(Fig. 1B).
The reproducibility was also calculated using the coefficient of
variation (CV) of the signal intensity from replicates of the UHRR
sample. To compare the CV values published in MAQC [4],
11,365 gene probes commonly present in both the 3D-Gene
TM
microarray and the probe set selected from the MAQC study were
used for the calculation. Only genes that were detected in at least
three of the five (60%) sample replicates for the non- and 1-round
amplification method, or at least two of the three (67%) replicates
for the 2-round amplification method were included in the CV
calculation. The numbers of detected genes meeting these criteria
were 10,012, 10,567 and 9,437 for the non-, 1- and 2-round
amplification methods, respectively. The replicate median
CV6standard deviation were 0.1760.10, 0.1360.08, 0.1760.13
for the non-, 1- and 2-round amplification methods, respectively
(Fig. 2).
Next, we evaluated the qualitative concordance of the detected
genes between the three sample preparation methods. More than
85% (20,717 of 24,267) genes were commonly detected by the
three preparation methods. 1.1% (259 of 24,267) genes were
uniquely detected by the non-amplification method while 1.7%
(409 of 24,267) genes were uniquely detected by the 1-round
amplification method (Fig. 3). It should be noted that the number
of overlapping genes detected by both the non- and 1-round
amplification methods (1,417 genes) is much larger than the
number of overlapping genes detected by both the non- and 2-
round amplification methods (45 genes). This suggests that
multiple rounds of amplification would create further diversion
in the expression profiles from the original unamplified profile.
Relative Accuracy
To assess the relative accuracy of the microarray data, an
alternative technology was used to measure gene expression. Four
different human RNA samples were processed by the non-, 1- or
2-round amplification method and analyzed by microarrays. The
Figure 1. Intra- and inter-method gene expression comparison using UHRR samples. 1A: Intra-method comparisons of UHRR assayed by
the non-amplification (Non-Amp), the 1-round amplification (1xAmp), and the 2-round amplification (2xAmp) method. 1B: Inter-method
comparisons between the non- and 1-round amplification methods, between the 1- and the 2-round amplification methods, and between the non-
and 2-round amplification methods. The scatter plots compare the logarithmic scale (base 10) signal intensities expressed by each gene from
duplicate microarray experiments. Pearson’s correlation coefficient (R) is in the top left corner of each plot.
doi:10.1371/journal.pone.0031397.g001
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analyzing the same samples. For this comparison, we selected 42
genes based on our preliminary study, 25 of which (#1–25 in
Table S1) were randomly selected and 17 of which (#26–42 in
Table S1) were selected due to their susceptibility to amplification
bias.
We found that the microarray data processed using the non-
amplification method had the highest Spearman’s correlation
(r=0.84–0.93) with the qRT-PCR data for all four RNA samples
(Fig. 4). Correlation with the qRT-PCR data decreased as the
rounds of amplification increased (r=0.44–0.74 for 1-round
amplification and r=0.29–0.62 for 2-round amplification). This
indicates that the amplification process during sample preparation
in fact reduces the relative accuracy of the microarray data.
The differential expression data obtained from Human Brain
Reference RNA (HBRR) and UHRR using the non-amplification
method were further compared to the qRT-PCR assay values
published in MAQC [4]. Out of 996 genes present both on the
microarray platform used in this study and the published qRT-
PCR assay, 732 genes were detected in both HBRR and UHRR
on the microarray and the qRT-PCR assay (Fig. 5). The
correlation between the non-amplification method on microarray
and the qRT-PCR assay was 0.903. By comparison, other
microarray platforms published in MAQC report the correlation
values of 0.839–0.905 [4].
Discussion
Comprehensive analyses of gene expression profiles using high-
throughput technologies such as microarray provide valuable
information useful for the elucidation of molecular mechanisms
and cellular functions. In many gene expression assays, the target
nucleic acids undergo preprocessing before microarray detection.
The most commonly used target RNA processing methods involve
linear amplification by in vitro transcription to complementary
RNA using T7 RNA polymerase [16]. Although amplification is
critical for some studies in which sample material is limited, it is
Figure 2. Intra-method reproducibility of gene expression
signals among replicates. HURR was assayed in replicates by the
non-amplification (Non-Amp), the 1-round amplification (1xAmp) or the
2-round amplification (2xAmp) method and detected by microarray. A
total of 11,365 genes present in both 3D-Gene
TM microarray and the
MAQC probe set were used for the calculation. The distributions of the
coefficient of variation (CV) are presented as boxes: the bottom and the
top of the box represent the 1
st and 3
rd quartile whereas the band near





Figure 3. Qualitative concordance of detected genes by three
sample preparation methods. Among 24,267 gene spots on the
microarray used, genes that were detected in at least 60% of the sample
replicates were used to create the Venn diagram.
doi:10.1371/journal.pone.0031397.g003
Figure 4. Spearman’s rank correlation between the microarray
assay and qRT-PCR assay. UHRR, HBRR, breast, and colon RNA
derived from human tissue or cells were processed by the non-
amplification (black bar), the 1-round amplification (grey bar), or the 2-
round amplification (white bar) method, analyzed by microarray. The
obtained PolR2A-normalized signal intensity (log2) of the 42 genes
(Table S1) was compared with DCt values of the same samples analyzed
by qRT-PCR assays.
doi:10.1371/journal.pone.0031397.g004
Figure 5. Correlation between microarray and MAQC qRT-PCR
assay. The scatter plot compares the log2 differential expression ratios
of HBRR versus UHRR obtained from the non-amplification method on
microarray and from qRT-PCR assays published in MAQC [4]. The
number of genes compared (n) and the Spearman’s correlation (r) are
listed in the top left corner of the plot. The diagonal line indicates the
ideal y=x line.
doi:10.1371/journal.pone.0031397.g005
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the initial transcript abundance. It is naturally drawn that direct
analysis of cDNA obtained by reverse transcription of RNA
samples would avoid such bias and therefore provide better fidelity
in the detection of transcript abundance. Using an unamplified
RNA sample, we previously reported the satisfactory performance
of 3D-Gene
TM microarray we had developed [13]; however, the
protocol used in the previous study showed relatively small fold-
changes in gene expression when samples derived from two
different tissues (human brain and liver) were analyzed.
In this study, we combined the 3D-Gene
TM microarray
platform with an improved non-amplification method for target
RNA preparation and demonstrated competitive reproducibility
and detection coverage. The CV for the 1-round amplification
method was similar to the median values (5–15%) reported in the
MAQC [4], whereas the CV values for the non- and 2-round
amplification method were slightly higher (17%). Importantly, the
non-amplification method showed better accuracy than the either
amplification method in all four types of human-derived tissue or
cellular RNA tested (Fig. 4). In Figure 1, we show that rounds of
amplification introduce the artificial diversity and compromise the
accuracy in measured transcript abundance. This is further
supported by strong correlation with qRT-PCR assay (Fig. 4).
We further validated the accuracy of the non-amplification
method by comparing the data obtained with qRT-PCR assays
published by MAQC [4]. Among the microarrays tested in the
MAQC, Eppendorf and National Cancer Institute (NCI) prepared
the RNA samples without using in vitro transcription amplification.
These are unique microarray platforms because Eppendorf is a
low-density array characterized by a unique data structure and
NCI uses dual-color labeling which defines the signal background
differently. Therefore, we believe that the results obtained from
these microarray platforms do not accurately evaluate true
potential of the non-amplification method. Herein, by utilizing
the mono-color labeling method and a comprehensive microarray
platform, we reevaluated the non-amplification method. Our non-
amplification method detected 732 out of 996 genes, the largest
detection coverage as the mono-color labeling method. In
addition, the correlation of our non-amplification method on
microarray with the qRT-PCR assays was one of the highest in the
seven platforms studied in MAQC [4].
Furthermore, using the same microarray platform and the same
labeling method, we directly compared the effect of the target
amplification on detection accuracy. This is indirectly estimated by
correlation with qRT-PCR, the current golden standard for gene
expression measurements. We found dramatic decreases in the
correlation coefficients as rounds of target amplification increased.
It should be noted that 17 of the 42 genes studied were pre-
selected due to their potential for amplification bias; therefore, the
effect of amplification bias might be less dramatic if the target
genes are expanded to include whole transcriptome analysis.
However, if genes that are particularly susceptible to amplification
bias are selected as targeted biomarkers in focused microarrays for
diagnostic use, the consequence of distorted measurements could
be devastating. It is imperative to choose a method that reflects
true transcript abundance, especially in clinical settings and
diagnostic tests.
It has been reported that gene expression data obtained from 1-
round amplified RNA is substantially different from data obtained
from 2-round amplified RNA. Croner et al. performed unsuper-
vised hierarchical cluster analyses that include all 22,283 probe
sets from the Affymetrix Gene chip and separated 1-round
amplified samples from 2-round amplified samples [17]. It is also
reported that the gene expression ratios of two samples (such as
treated versus untreated) tend to decrease when the amplification
procedure is used. Gilbert et al. reported that half of differentially
expressed candidate genes were undetectable using the recom-
mended amplification procedure, thus distorting the true propor-
tional differences [18]. In an effort to explain the observed bias,
this group investigated T7 in vitro transcription reaction kinetics
and discovered that aRNA production was linear only for 40 min
of the first round and for 50 min of the second round
amplification. This is followed by a non-linear phase, which
introduces the bias that leads to inaccuracies in transcript
abundance [18]. However, many in vitro transcription protocols
(including Arcturus
TM RiboAmpH HS PLUS, Ambion’s Messa-
geAmp
TM II and Epicentre’s TargetAmp
TM) recommend 4–
14 hours of the incubation, thereby providing idling time for non-
linear RNA amplification and subsequent bias. Our current study
further supports the conclusion of Gilbert et al. that the non-
amplification method generates larger gene expression ratios and
thus more differentially expressed genes than amplification
methods do.
Other explanations of the amplification bias have been
hypothesized. Kerkhoven et al. reported that T7-based linear
amplification bias is caused by the 39 spacer sequence of the
amplified RNA, which excessively binds to probes that share
similar sequence with the T7 motifs [19]. It has also been reported
that amplification bias is caused by molecular features of the
affected RNA sequences, including the position within the gene,
the GC content, hairpin numbers, and the length of poly-A
stretches [20–22].
We assume that the better accuracy obtained by the non-
amplification method compared to the 1-round amplification
method in this study is due to the absence of these molecular
hindrances. Additionally, we attribute our improved results to two
factors that enhanced signal intensity: satisfactory performance of
our microarray platform [13] and use of a signal amplifier such as
dendrimer [23] in the sample labeling process.
Another advantage of the non-amplification method is the
shorter processing time (currently several hours) compared to
amplification methods (1.5 days). This directly translates to lower
labor costs. Finally, the simplicity of the procedure is also
advantageous if the system is to be automated, which is necessary
for applying the methods in a clinical setting.
Despite our current improvements, the non-amplification
method as presented can be further refined. Nearly all of the
non-amplification data presented herein were produced using
10 mg of total RNA. Similar reproducibility (R=0.984) was
observed for the non-amplification method when the amount of
RNA was reduced from 10 mgt o3mg (data not shown). This
quantity is still too large for specific study settings, such as small
tissue biopsies or laser micro-dissection samples. However, this
method can be applied to researches that have less stringency in
sample limitations, including studies that involve cell culture or
large surgical specimens.
One way to reduce the input RNA quantity while maintaining
the reaction concentration is to engineer a device that decreases
the hybridization reaction volume. The hybridization reaction
volume used in this study was 210 ml. If the hybridization reaction
volume is decreased to 10 ml, which is quite feasible, the amount of
sample RNA could be 20-fold smaller or ,150 ng. Additionally, if
the analysis is not for the whole transcriptome but targeted to a
limited number of genes, the size of the system can be further
reduced. These allow the method to be more accessible for various
studies, including diagnostic testing. For example, MammaPrintH,
an in vitro diagnostic test based on gene expression microarray
requires 200 ng total RNA extracted from biopsy or surgical
Non-Amplified RNA Samples for Gene Expression
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sample quantity are necessary before the non-amplification
method can be used in a wide range of clinical research and tests.
We have demonstrated that our RNA preprocessing method
that does not involve sample amplification is accurate in transcript
measurement, thus providing reliable gene expression profiles.
When combined with micro-columnar 3D-Gene
TM microarray
technology, this non-amplification method can be employed for a




The following commercially available total RNA was used in
this study: Universal Human Reference RNA (UHRR, Stratagene
#740000), Human Brain Reference RNA (HBRR, Applied Bio-
systems #AM6051), human breast total RNA (Applied Biosystems
#AM6952) and human colon total RNA (Applied Biosystems
#AM7986).
Non-amplified sample preparation and hybridization to
microarray
10 mg total RNA was used unless otherwise indicated. The RNA
and 2 ml Anchored Oligo dT20 (2.5 mg/ml Invitrogen #55117)
were added to nuclease-free H2O to a final volume of 20 ml and
incubated at 80uC for 10 min, then immediately placed on ice for
3 min. The RNA was reverse transcribed using SuperScriptHII kit
(Invitrogen #18064-014) with 4 ml of 0.16 mM dNTP mixture
and 2 ml Biotin-16-dUTP (1 mM, Roche Diagnostic #1093070),
incubated at 42uC for 2 hrs. Nuclease-free H2O (156 ml) and 4 ml
1.0 M NaOH were added to the cDNA product and incubated at
37uC for 10 min. For alkaline neutralization, 20 ml 1 M Tris-HCl
(pH 6.8) was added. The cDNA was purified using DNA Clean &
Concentrator-5 columns (Zymo, #D4013). The concentration of
the obtained cDNA was measured using a spectrophotometer
(Nanodrop ND-1000 version 3.0.0., NanoDrop Technologies).
The cDNA was mixed with 21 mg of each human and yeast
non-coding nucleic acid sequence as a blocking agent and
nuclease-free H2O was added to a final volume of 47.3 ml. The
mixture was denatured at 95uC for 5 min then immediately placed
on ice for 3 min. This cDNA mixture was added to 162.7 mlo f
42uC pre-warmed hybridization buffer which includes formamide
and SDS. The hybridization mixture was vacuumed at 0.01 MPa
for 20 min, incubated at 42uC for 3 min and applied to the 3D-
Gene
TM Human Oligo chip 25 k (Toray Industries, Inc. TRT-
XR125). The microarrays were hybridized on a 250 rpm shaker at
42uC for 16 hrs as recommended by the manufacturer.
The microarrays were washed as described in the product
manual (v1.06). The spin-dried microarray underwent the post-
labeling procedure. First, 2.0 ml UltraAmp
TM SA (40) Oyster-650
(Genisphere Inc. #SA0460) and 2.0 ml UltraAmp
TM SA (40)
Nucleic Acid Blocker (Genisphere Inc. #SA04BLK) were mixed
with 125 ml 2X post-labeling buffer, as per the manufacturer’s
instructions and H2O was added to a final volume of 250 ml. This
post-labeling reagent mixture was incubated at 4uC for 5 min and
applied to the hybridized microarray, which was attached and
enclosed with a plastic cover with double-sided adhesive tape. The
holes in the microarray were sealed with tape and incubated at
4uC for 30 min in dark. After the labeling reaction, the plastic
cover was removed from the microarray and it was washed as
described in the product manual (v1.06). The microarray was then
spin dried, followed by the image scanning.
Amplified sample preparation
For both 1- and 2-round amplification methods, sample
preparation, hybridization, and washing were performed accord-
ing to the 3D-Gene
TM Human Oligo chip 25K manual (v1.06).
The linear amplification of RNA samples was performed using the
Ambion’s Amino Allyl MessageAmp
TM II aRNA Amplification
Kit (Ambion, #AM1753), per the manufacturer’s instructions.
Image scanning and analysis of gene expression
Microarrays were scanned using ScanArrayH Lite (Perkin
Elmer) at an excitation wavelength of 635 nm with 100% laser
power. The photomultiplier settings of the red channel were
manually adjusted according to procedures recommended by
the manufacturer. The obtained images were numerated by
GenePixH Pro6.0 (Molecular Device) and the spot intensity was
calculated by taking the median intensity of the foreground
signals. The background signal intensity is derived by taking the
mean signal intensity of the blank spots that excludes the top and
bottom 5% signal intensities. The detected spots were defined as
those that had signal intensity above the 95% upper confidence
interval of the background signal intensity. For detected spots,
their signal intensities were determined after subtracting with
the mean background signal. For data comparison, the
background-subtracted signal intensity was normalized using
global normalization in which the median from each microarray
was used.
All microarray data from this study are complaint with Minimum
Information About a Microarray Experiment (MIAME) and is
publicly available through the NCBI’s Gene Expression Omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/projects/geo/) un-
der the series record GSE30945. The accession numbers are listed
in Table S2 (Supporting Information).
To assess the signal reproducibility of each sample preparation
method, the Pearson’s correlation coefficient (R) and the
coefficient of variation (CV) of the signal were calculated. The
CV for each mRNA assessment was calculated by the formula
CV%=(standard deviation/mean)6100.
Real-Time PCR
The relative accuracy of the data obtained by microarray was
evaluated by comparing them with data obtained from an
alternative detection technology. TaqManH assays (Applied
Biosystems), one of the most accurate methods in the quantitative
real-time PCR (qRT-PCR) system, were used in this assessment,
per the manufacturer’s instructions. Forty-two genes were used for
this comparison (Table S1). qRT-PCR was performed for each
gene in quadruplicate and the mean was calculated as the
threshold cycle (Ct) value. Each Ct value was normalized to the Ct
of the PolR2A gene and calculated as DCt [4,25]. For data
comparison between microarray and qRT-PCR, the Spearman’s
correlation coefficient (r) was used.
Comparing the qRT-PCR assays of HBRR versus UHRR
published in MAQC [4], 996 genes out of 1,045 genes cited in the
publication matched with gene probes carried on the 3D-Gene
TM
Human Oligo chip 25K. Following the MAQC protocol, genes
detected in at least three of the five replicate samples from both
assays were used for the analysis.
Supporting Information
Table S1 DCt values of 42 genes detected from four human
derived RNA samples analyzed by qRT-PCR.
(DOC)
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